Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06413654 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06413654 · ClinicalTrials.gov record · last posted 2026-05-05

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

StatusRecruiting
PhasePhase 2/3
Started2024-07-17
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.

Amendment record 6 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 6 times since 2024-05-13; most recent amendment 2026-04-29. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-07-22
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT06413654
Lead Sponsor Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborators: Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Neuromyelitis Optica Spectrum Disorders
Enrollment 132 participants
Start Date 2024-07-17
Primary Completion 2027-10-31 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-05